Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016 Jan 9;2016(1):CD006014.
doi: 10.1002/14651858.CD006014.pub7.

Interval debulking surgery for advanced epithelial ovarian cancer

Siriwan Tangjitgamol  1 , Sumonmal Manusirivithaya, Malinee Laopaiboon, Pisake Lumbiganon, Andrew Bryant
Affiliations
Meta-Analysis

Interval debulking surgery for advanced epithelial ovarian cancer

Siriwan Tangjitgamol et al. Cochrane Database Syst Rev. .

Abstract

Background: Interval debulking surgery (IDS), following induction or neoadjuvant chemotherapy, may have a role in treating advanced epithelial ovarian cancer (stage III to IV) where primary debulking surgery is not an option.

Objectives: To assess the effectiveness and complications of IDS for women with advanced stage epithelial ovarian cancer.

Search methods: We searched the Cochrane Gynaecological Cancer Group's Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL) 2012, Issue 6, MEDLINE and EMBASE for the original review in to June 2012. We updated the searches in June 2009, 2012 and 2015 for the review updates.

Selection criteria: Randomised controlled trials (RCTs) comparing survival of women with advanced epithelial ovarian cancer, who had IDS performed between cycles of chemotherapy after primary surgery with survival of women who had conventional treatment (primary debulking surgery and adjuvant chemotherapy).

Data collection and analysis: Two review authors independently assessed trial quality and extracted data. Searches for additional information from study authors were attempted. We performed meta-analysis of overall and progression-free survival (PFS), using random-effects models.

Main results: Three RCTs randomising 853 women, of whom 781 were evaluated, met the inclusion criteria. Meta-analysis of three trials for overall survival (OS) found no statistically significant difference between IDS and chemotherapy alone (hazard ratio (HR) = 0.80, 95% confidence interval (CI) 0.61 to 1.06, I² = 58%). Subgroup analysis for OS in two trials, where the primary surgery was not performed by gynaecologic oncologists or was less extensive, showed a benefit of IDS (HR = 0.68, 95% CI 0.53 to 0.87, I² = 0%). Meta-analysis of two trials for PFS found no statistically significant difference between IDS and chemotherapy alone (HR = 0.88, 95% CI 0.57 to 1.33, I² = 83%). Rates of toxic reactions to chemotherapy were similar in both arms (risk ratio = 1.19, 95% CI 0.53 to 2.66, I² = 0%), but little information was available for other adverse events or quality or life (QoL).

Authors' conclusions: We found no conclusive evidence to determine whether IDS between cycles of chemotherapy would improve or decrease the survival rates of women with advanced ovarian cancer, compared with conventional treatment of primary surgery followed by adjuvant chemotherapy. IDS appeared to yield benefit only in women whose primary surgery was not performed by gynaecologic oncologists or was less extensive. Data on QoL and adverse events were inconclusive.

PubMed Disclaimer

Conflict of interest statement

There is no known conflict of interest among the authors of this review.

Figures

1
1
Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.
2
2
Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
3
3
Study flow diagram.
1.1
1.1. Analysis
Comparison 1 IDS vs chemotherapy only, Outcome 1 Overall survival.
1.2
1.2. Analysis
Comparison 1 IDS vs chemotherapy only, Outcome 2 Progression‐free survival.
1.3
1.3. Analysis
Comparison 1 IDS vs chemotherapy only, Outcome 3 Toxic reactions to chemotherapy.
1.4
1.4. Analysis
Comparison 1 IDS vs chemotherapy only, Outcome 4 Peripheral neuropathy of grade 2 or higher.
1.5
1.5. Analysis
Comparison 1 IDS vs chemotherapy only, Outcome 5 Grade 3 or 4 gastrointestinal adverse events.
1.6
1.6. Analysis
Comparison 1 IDS vs chemotherapy only, Outcome 6 Grade 4 pulmonary adverse events.
1.7
1.7. Analysis
Comparison 1 IDS vs chemotherapy only, Outcome 7 Grade 4 cardiovascular adverse events.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Redman 1994 {published data only}
    1. Redman CW, Warwick J, Luesley DM, Varma R, Lawton FG, Blackledge GR. Intervention debulking surgery in advanced epithelial ovarian cancer. British Journal of Obstetrics and Gynaecology 1994;101:142‐6. - PubMed
    1. Varma R, Blackledge G, Redman C, Luesley D, Chan KK, Mould J. A randomised trial of intervention debulking surgery and the duration of cis‐platinum combination chemotherapy in advanced epithelial ovarian cancer (EOC). Annals of Oncology. 1990; Vol. 1 (Suppl 9):4.
Rose 2004 {published data only}
    1. Rose PG, Nerenston S, Brady MF, Clarke Pearson D, Olt G, Rubin SC, et al. Operative morbidity following primary and interval debulking surgery for advanced ovarian cancer. Proceedings of the American Society of Clinical Oncology. 2004; Vol. 23:450.
    1. Rose PG, Nerenstone S, Brady M, Clarke Pearson D, Olt G, Rubin SC, et al. A phase III randomised study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease: a Gynecologic Oncology Group study. Proceedings of the American Society of Clinical Oncology. 2002; Vol. 21 (Pt 1):201a.
    1. Rose PG, Nerenstone S, Brady MF, Clarke‐Pearson D, Olt G, Rubin SC, et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. The New England Journal of Medicine 2004;351:2489‐97. - PubMed
Van der Burg 1995 {published data only}
    1. Burg ME, Coens C, Lent M, Kobierska A, Colombo N, Favalli G, et al. After ten years follow‐up interval debulking surgery remains a significant prognostic factor for survival and progression free survival for advanced ovarian cancer: the EORTC Gynaecological Cancer Group study. International Journal of Gynecological Cancer. 2004; Vol. 14 (Suppl 1):3.
    1. Burg ME, Lent M, Kobierska A, Colombo N, Favalli G, Lacave AJ, et al. Intervention debulking surgery (IDS) does improve survival in advanced epithelial ovarian cancer (EOC); an EORTC gynecological cancer cooperative group (GCCG) study. Proceedings of the American Society of Clinical Oncology. 1993; Vol. 12:258.
    1. Burg ME, Lent M, Kobierska A, Colombo N, Favalli G, Lacave AJ, et al. Intervention debulking surgery (IDS) does increase survival in advanced epithelial ovarian cancer (OC) ‐ an EORTC Gynecological Cancer Cooperative Group (GCCG) study. European Journal of Cancer. 1993; Vol. 29 (Suppl 6):S132.
    1. Burg MEL, Coens C, Lent M, Kobierska A, Colombo M, Favalli G, et al. The survival benefit of interval debulking surgery (IDS) in advanced ovarian cancer is maintained during ten years; the EORTC GCG 55865 study. International Journal of Gynecologic Cancer. 2005; Vol. 15 (supplement 2):79.
    1. Burg MEL, Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the EORTC. The New England Journal of Medicine 1995;332(10):629‐34. - PubMed

References to studies excluded from this review

Angioli 2006 {published data only}
    1. Angioli R, Palaia I, Zullo MA, Muzii L, Manci N, Calcagno M, et al. Diagnostic open laparoscopy in the management of advanced ovarian cancer. Gynecologic Oncology 2006;100:455‐61. - PubMed
Chan 2003 {published data only}
    1. Chan YM, Ng TY, Ngan HY, Wong LC. Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study. Gynecologic Oncology 2003;88:9‐16. - PubMed
Dutta 2005 {published data only}
    1. Dutta T, Sharma H, Kumar L, Dinda AK, Kumar S, Bhatla N, et al. Neoadjuvant chemotherapy for epithelial ovarian cancer‐‐role of apoptosis. Cancer Chemotherapy and Pharmacology 2005;56(4):427‐35. - PubMed
Evdokimova 1982 {published data only}
    1. Evdokimova NI, Grigorova TM. Comparative study of 2 combined treatment regimens in stage‐III to ‐IV ovarian cancer. Voprosy onkologii 1982;28(7):28‐34. - PubMed
Fuso 2006 {published data only}
    1. Fuso L, Amant F, Neven P, Berteloot P, Vergote I. Gemcitabine‐carboplatin‐paclitaxel combination as first‐line therapy in advanced ovarian carcinoma: A single institution phase II study in 24 patients. International Journal of Gynecological Cancer 2006;16 (Suppl 1):60‐7. - PubMed
Giannopoulos 2006 {published data only}
    1. Giannopoulos T, Butler‐Manuel S, Taylor A, Ngeh N, Thomas H. Clinical outcomes of neoadjuvant chemotherapy and primary debulking surgery in advanced ovarian carcinoma. European Journal Gynaecologic Oncology 2006;27:25‐8. - PubMed
Ikeba 2004 {published data only}
    1. Ikeba K, Okubo M, Takeda S, Kinoshita K, Maeda H. Five‐year results of cyclic semi‐high dose neoadjuvant chemotherapy supported by autologous peripheral blood stem‐cell transplantation in patients with advanced ovarian cancer. International Journal Clinical Oncology 2004;9:113‐9. - PubMed
Kuhn 2001 {published data only}
    1. Kuhn W, Rutke S, Spathe K, Schmalfeldt B, Florack G, Hundelshausen B, et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis. Cancer 2001;92:2585‐91. - PubMed
Kumar 2009 {published data only}
    1. Janga D, Kumar L, Kumar S, Shukla NK, Thulkar S, Singh R. Neoadjuvant chemotherapy (CT) followed by debulking surgery vs upfront surgery followed by chemotherapy in advanced epithelial ovarian carcinoma (EOC): a prospective, randomized study. Proceedings of the American Society of Clinical Oncology 2003. 2007; Vol. 22:487:Abstract 1957.
    1. Kumar L, Hariprasad R, Kumar S, Bhatla N, Thulkar S, Vijayaraghavan M, et al. Neoadjuvant chemotherapy followed by interval debulking surgery versus upfront surgery followed by chemotherapy in advanced epithelial ovarian carcinoma: a prospective randomized study ‐ interim results. Proceeding of the ASCO Annual Meeting 2007, Part I. 2007; Vol. 28, issue 18 (Suppl):Abstract 5531.
    1. Kumar L, Hariprasad R, Kumar S, Bhatla N, Thulkar S, Shukla NK . Neo‐adjuvant chemotherapy in advanced epithelial ovarian cancer (eoc): A prospective, randomized study. Indian Journal of Medical and Paediatric Oncology 2009;30(1):15. [NCT00715286]
Lee 2006 {published data only}
    1. Lee SJ, Kim BG, Lee JW, Park CS, Lee JH, Bae DS. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery. Journal of Obstetric and Gynaecological Research 2006;32:99‐106. - PubMed
Liu 2004 {published data only}
    1. Liu EL, Mi RR. Neoadjuvant intraarterial chemotherapy and embolization in treatment of advanced ovarian epithelial carcinoma. Chinese Medical Journal 2004;117:1547‐51. - PubMed
Madhuri 2014 {published data only}
    1. Madhuri TK, Ashbourne W, Butler‐Manuel SA, Tailor A. RCT to evaluate utility and efficacy of neutral argon plasma as new technology in achieving complete cytoreduction of advanced epithelial ovarian carcinoma‐initial feasibility study. 15th Biennial Meeting of the International Gynecologic Cancer Society Melbourne, VIC Australia.. 2014; Vol. 245.
Matulonis 2009 {published data only}
    1. Matulonis UA, Krag KJ, Krasner CN, Atkinson T, Horowitz NS, Lee H, et al. Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Mullerian tumors. Gynecologic Oncology 2009;112(2):394‐399. - PubMed
Onda 2009 {published data only}
    1. Onda T, Kobayashi H, Nakanishi T, Hatae M, Iwasaka T, Konishi I, et al. Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206. Gynecologic Oncology 2009;113(1):57‐62. - PubMed
Onda 2014 {published data only}
    1. Onda T, Yoshikawa H, Shibat a T, Nakamura K, Satoh T, Saito T, et al. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in phase III randomized trial: JCOG0602. Journal of Clinical Oncology. 2014; Vol. 32:suppl; abstr 5508.
Park‐Simon 2006 {published data only}
    1. Park‐Simon T, Jänicke F, Ortmann O, Hilfrich J, Breitbach G, Höss C, et al. A randomized multicenter phase II study on neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian carcinomas (PRIMOVAR). Journal of Clinical Oncology: 2006 ASCO Annual meeting proceedings 2006;24(18S (June 20 Supplement)):Abstract 15025.
Polcher 2009 {published data only}
    1. Polcher M, Mahner S, Ortmann O, Hilfrich J, Diedrich K, Breitbach GP, et al. Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancer‐‐a prospective multicenter phase II trial (PRIMOVAR). Oncology Reports 2009;22(3):605‐613. - PubMed
Recchia 2001 {published data only}
    1. Recchia F, Filippis S, Rosselli M, Saggio G, Carta G, Rea S. Primary chemotherapy in stage IV ovarian cancer. A prospective phase II study. European Journal of Gynaecologic Oncology 2001;22:287‐91. - PubMed
Solomon 1988 {published data only}
    1. Solomon J. The role of surgical reexploration following chemotherapy in ovarian cancer. Australian and New Zealand Journal of Obstetrics and Gynaecology 1988;28:121‐6. - PubMed
Tiersten 2009 {published data only}
    1. Tiersten AD, Liu PY, Smith HO, Wilczynski SP, Robinson WR III, Markman M, et al. Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelail ovarian, fallopian tube or primary peritoneal cancer: Soutwest Oncology Group Study S0009. Gynecologic Oncology 2009;112:444‐9. - PMC - PubMed
Vergote 2010 {published data only}
    1. EORTC 55971. A randomized phase III study comparing upfront debulking surgery vs neo‐adjuvant chemotherapy in patients with stage IIIc or IV epithelial ovarian carcinoma. IGCS 12th Biennial Meeting. 2008.
    1. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. European Organization for Research and Treatment of Cancer‐Gynaecological Cancer Group, NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. New England Journal of Medicine 2010;363(10):943‐53. - PubMed

Additional references

Ansquer 2001
    1. Ansquer Y, Leblanc E, Clough K, Morice P, Dauplat J, Mathevet P, et al. Neoadjuvant chemotherapy for unresectable ovarian carcinoma. Cancer 2001;91:2329‐34. - PubMed
Bristow 2002
    1. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta‐analysis. Journal of Clinical Oncology 2002;20:1248‐59. - PubMed
Bristow 2006
    1. Bristow RE, Chi DS. Platinum‐based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta‐analysis. Gynecologic Oncology 2006;103(3):1070‐6. - PubMed
Bristow 2007
    1. Bristow RE, Eisenhauer EL, Santillan A, Chi DS. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecologic Oncology 2007;104(2):480‐90. - PubMed
Bucher 1997
    1. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta‐analysis of randomized controlled trials. Journal of Clinical Epidemiology 1997;50(6):683‐91. - PubMed
Cochrane Handbook
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Deeks 2001
    1. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta‐analysis. Egger M, Davey Smith G, Altman DG (eds). Systematic Reviews in Health Care: Meta‐Analysis in Context (2nd edition). BMJ Publication Group, London, 2001.
DerSimonian 1986
    1. DerSimonian R, Laird N. Meta‐analysis in clinical trials. Controlled Clinical Trials 1986;7:177‐88. - PubMed
Elattar 2011
    1. Elattar A, Bryant A, Winter‐Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2011, Issue 8. [DOI: 10.1002/14651858.CD007565.pub2] - DOI - PMC - PubMed
Elit 1995
    1. Elit A, Carey M. The role of interval debulking surgery in advanced ovarian cancer: a meta‐analysis. International Journal of Gynecological Cancer. 1995; Vol. 5 (Suppl 1):37 (abstract).
Fanfani 2003
    1. Fanfani F, Ferrandina G, Corrado G, Fagotti A, Vito Zakut H, Mancuso S, et al. Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIc ovarian cancer patients. Oncology 2003;65:316‐22. - PubMed
Griffiths 1975
    1. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Journal of the National Cancer Institute Monographs 1975;42:101‐4. - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327:557‐60. - PMC - PubMed
Hoskin 1994
    1. Hoskins WJ, McGuire WP, Brady MF, Homsley HD, Creasman WT, Berman M, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. American Journal of Obstetrics and Gynecology 1994;170:974‐80. - PubMed
Jacob 1991
    1. Jacob JH, Gerhenson DM, Morris M, Copeland LJ, Burke TW, Wharton JT. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecologic Oncology 1991;42:146‐50. - PubMed
Kayikçioglu 2001
    1. Kayikçioglu F, Köse MF, Boran N, Caliskan E, Tulunay G. Neoadjuvant chemotherapy or primary surgery in advanced ovarian carcinoma.. International Journal of Gynecological Cancer 2001;11(6):446‐70. - PubMed
Kehoe 1995
    1. Kehoe S, Shafi M, Luesley D, Neijt JP, Cannistra SA, Burg MEL, et al. Interval cytoreduction in ovarian cancer. New England Journal of Medicine 1995;333:254‐5. - PubMed
Lawton 1989
    1. Lawton FG, Redman CW, Luesley DM, Chan KK, Blackledge G. Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer. Obstetrics and Gynecology 1989;73:61‐5. - PubMed
Loizzi 2005
    1. Loizzi V, Cormio G, Resta L, Rossi CA, Gilio AR, Cuccovillo A, et al. Neoadjuvant chemotherapy in advanced ovarian cancer: a case‐control study. International Journal of Gynecological Cancer 2005;15:217‐23. [MEDLINE: ] - PubMed
Mazzeo 2003
    1. Mazzeo F, Berliere M, Kerger J, Squifflet J, Duck L, D'Hondt V, et al. Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced‐stage ovarian cancer. Gynecologic Oncology 2003;90:163‐9. - PubMed
Morice 2003
    1. Morice P, Dubernard G, Rey A, Atallah D, Pautier P, Pomel C, et al. Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. Journal of the American College of Surgeons 2003;197:955‐63. - PubMed
Morrison 2012
    1. Morrison J, Haldar K, Kehoe S, Lawrie TA. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database of Systematic Reviews 2012, Issue 8. [DOI: 10.1002/14651858.CD005343.pub3] - DOI - PMC - PubMed
Parmar 1998
    1. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815‐34. - PubMed
Schwartz 1999
    1. Schwartz PE, Rutherford TJ, Chambers JT, Kohorn EI, Thiel RP. Neoadjuvant chemotherapy for advanced ovarian cancer:long term survival. Gynecologic Oncology 1999;72:93‐9. - PubMed
Shibata 2003
    1. Shibata K, Kikkawa F, Mika M, Suzuki Y, Kajiyama H, Ino K, et al. Neoadjuvant chemotherapy for FIGO stage III or IV ovarian cancer: Survival benefit and prognostic factors. International Journal of Gynecological Cancer 2003;13:587‐92. - PubMed
Surwit 1996
    1. Surwit E, Childers J, Atlas I, Nour M, Hatch K, Hallum A, et al. Neoadjuvant chemotherapy for advanced ovarian cancer. International Journal of Gynecological Cancer 1996;6:356‐61.
Torre 2015
    1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‐Tieulent J, Jemal A. Global cancer statistics 2012. CA: a Cancer Journal for Clinicians 2015;65(2):87‐108. - PubMed
Van der Burg 2003
    1. Burg ME, Vergote I, Gynecological Cancer Group of the EORTC. The role of interval debulking surgery in ovarian cancer. Current Oncology Reports 2003;5:473‐81. - PubMed
Van der Burg 2005
    1. Burg MEL, Coens C, Lent M, Kobierska A, Colombo M, Favalli G, et al. The survival benefit of interval debulking surgery (IDS) in advanced ovarian cancer is maintained during ten years; the EORTC GCG 55865 study. International Journal of Gynecologic Cancer. 2005; Vol. 15 (supplement 2):79.
Vergote 1998
    1. Vergote I, Wever I, Tjalma W, Gramberen M, Decloedt J, Dam P. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecologic Oncology 1998;71:431‐6. - PubMed
Wenzel 2005
    1. Wenzel L, Huang HQ, Monk BJ, Rose PG, Cella D. Quality‐of‐life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study. Journal of Clinical Oncology 2005;23:5605‐12. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources